CAI — Caris Life Sciences, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$25.00
+$0.22 (+0.89%)
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ. It is led by David Dean Halbert M.D., based in 750 West John Carpenter Freeway, Irving, TX, United States, 75039, with about 1,846 employees. Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Latest reported CAI revenue for 2025-09-30 was $216.8M. Net income was $24.3M. Revenue was up 19.5% from 2025-06-30 to 2025-09-30. CAI currently screens at market cap $5.22B.
Use this CAI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CAI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CAI SEC filings page. Lician reads the product cache first so this HTML stays unique to Caris Life Sciences, Inc. Common Stock even when a live quote feed is slow.
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
CAI Key Statistics
Market Cap
$5.22B
Volume
6.82M
Previous Close
$26.13
Day Range
$25.77 – $28.32
P/B Ratio
8.66
EPS
$0.08
Revenue
$216.83M
Net Income
$24.32M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+19.5%
Profit Margin
11.2%
Employees
1,846
CAI Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2025 | FY2024 | FY2024 |
|---|---|---|---|---|
| Revenue | $216.83M | $181.40M | $101.62M | $100.05M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $24.32M | -$71.79M | -$67.73M | -$66.19M |
| EPS (Diluted) | $0.08 | -$7.97 | -$2.59 | -$2.54 |
Total Assets
$984.57M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$753.22M
Operating Cash Flow
$38.38M
Free Cash Flow
$0.00
Caris Life Sciences, Inc. Common Stock Company Information
- Chairman, CEO & Founder
- David Dean Halbert M.D.
- Headquarters
- 750 West John Carpenter Freeway, Irving, TX, United States, 75039
- Website
- www.carislifesciences.com
- Phone
- 866 771 8946
- IPO / Founded
- 2025-06-18
- Sector
- Healthcare
- Industry
- Biotechnology